Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 3/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.34 |
| ▸ | CDC7 | O00311 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.34 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | CPT1A | P50416 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4323190 | 0.91 | CHEK2 (0.42) | AOC3NPC1RAB9ASCN9ADHODH | |
| SCHEMBL5001287 | 0.91 | AOC3 (0.43) | AOC3NPC1RAB9ASCN9ADHODH | |
| SCHEMBL4327229 | 0.87 | SCN9A (0.42) | AOC3NPC1RAB9ASCN9ACHEK2 | |
| SCHEMBL13913158 | 0.86 | ADORA2A (0.42) | AOC3NPC1RAB9ASCN9ACDC7 | |
| SCHEMBL4324627 | 0.85 | NPC1 (0.42) | AOC3NPC1RAB9ASCN9ADHODH | |
| SCHEMBL13993228 | 0.85 | AOC3 (0.41) | AOC3NPC1RAB9ASCN9ADHODH | |
| SCHEMBL4321753 | 0.85 | AOC3 (0.38) | AOC3NPC1RAB9ASCN9ADHODH | |
| SCHEMBL4320588 | 0.84 | CHEK2 (0.42) | AOC3NPC1RAB9ACHEK2FYN | |
| SCHEMBL4320141 | 0.84 | CHEK2 (0.42) | AOC3NPC1RAB9ACHEK2FYN | |
| SCHEMBL4314151 | 0.83 | SCN9A (0.46) | AOC3SCN9ACHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090074890-A1 | Substituted Triazoles as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2009-03-19 | — | — | US | disclosed |
| US-20090074890-A1 | Substituted Triazoles as Sodium Channel Blockers | MERCK SHARP & DOHME CORP. | 2009-03-19 | — | — | US | disclosed |
| US-7459475-B2 | Substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-7459475-B2 | Substituted triazoles as sodium channel blockers | MERCK & CO. INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20060020006-A1 | Substituted triazoles as sodium channel blockers | MERCK SHARP & DOHME LLC | 2006-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090074890-A1 | Substituted Triazoles as Sodium Channel Blockers | TRPV1, SCN3A, SCN5A | AOC3 2903/4885NPC1 910/4885RAB9A 2241/4885 |
| US-20060020006-A1 | Substituted triazoles as sodium channel blockers | TRPV1, SCN3A, SCN5A | AOC3 3035/4885NPC1 932/4885RAB9A 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.